Pelletier, Frederic, Comte, Virginie, Massard, Alexandre, Wenzel, Margot, Toulot, Stephanie, Richard, Philippe, Picquet, Michel, Le Gendre, Pierre, Zava, Olivier, Edafe, Fabio, Casini, Angela  ORCID: https://orcid.org/0000-0003-1599-9542 and Dyson, Paul J.
2010.
Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties.
Journal of Medicinal Chemistry
53
(19)
, pp. 6923-6933.
10.1021/jm1004804
|
Abstract
A series of bimetallic titanium−ruthenium complexes of general formula [(η5-C5H5)(μ-η5:κ1-C5H4(CR2)nPR′R′′)TiCl2](η6-p-cymene)RuCl2 (n = 0, 1, 2 or 4; R = H or Me; R′ = H, Ph, or Cy; R′′ = Ph or Cy) have been synthesized, including two novel compounds as well as two cationic derivatives of formula [(η5-C5H5)(μ-η5:κ1-C5H4(CH2)nPPh2)TiCl2] [(η6-p-cymene)RuCl](BF4) (n = 0 or 2). The solid state structure of two of these compounds was also established by X-ray crystallography. The complexes showed a cytotoxic effect on human ovarian cancer cells and were markedly more active than their Ti or Ru monometallic analogues titanocene dichloride and RAPTA-C, respectively. Studies of cathepsin B inhibition, an enzyme involved in cancer progression, showed that enzyme inhibition by the bimetallic complexes is influenced by the length of the alkyl chain in between the metal centers. Complementary ESI-MS studies provided evidence for binding of a Ru(II) fragment to proteins.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Chemistry |
| Subjects: | Q Science > QD Chemistry R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Publisher: | American Chemical Society |
| Last Modified: | 31 Oct 2022 08:58 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/79338 |
Citation Data
Cited 95 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric